ZA200603547B - Method for preparing submicron particles of paclitaxel - Google Patents

Method for preparing submicron particles of paclitaxel Download PDF

Info

Publication number
ZA200603547B
ZA200603547B ZA200603547A ZA200603547A ZA200603547B ZA 200603547 B ZA200603547 B ZA 200603547B ZA 200603547 A ZA200603547 A ZA 200603547A ZA 200603547 A ZA200603547 A ZA 200603547A ZA 200603547 B ZA200603547 B ZA 200603547B
Authority
ZA
South Africa
Prior art keywords
solvent
particles
suspension
water
solution
Prior art date
Application number
ZA200603547A
Other languages
English (en)
Inventor
Chaubal Mahesh
Werling Jane
Barrett E Rabinow
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of ZA200603547B publication Critical patent/ZA200603547B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
ZA200603547A 2003-11-07 2006-05-04 Method for preparing submicron particles of paclitaxel ZA200603547B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/703,395 US8067032B2 (en) 2000-12-22 2003-11-07 Method for preparing submicron particles of antineoplastic agents

Publications (1)

Publication Number Publication Date
ZA200603547B true ZA200603547B (en) 2007-04-25

Family

ID=34590725

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603547A ZA200603547B (en) 2003-11-07 2006-05-04 Method for preparing submicron particles of paclitaxel

Country Status (17)

Country Link
US (2) US8067032B2 (ko)
EP (1) EP1682116B1 (ko)
JP (1) JP2007510657A (ko)
KR (1) KR101152458B1 (ko)
CN (1) CN100551365C (ko)
AU (1) AU2004289233B2 (ko)
BR (1) BRPI0416239A (ko)
CA (1) CA2540383A1 (ko)
DK (1) DK1682116T3 (ko)
ES (1) ES2388924T3 (ko)
IL (1) IL174031A (ko)
NO (1) NO20062552L (ko)
NZ (1) NZ546439A (ko)
PL (1) PL1682116T3 (ko)
RU (1) RU2402313C2 (ko)
WO (1) WO2005046671A1 (ko)
ZA (1) ZA200603547B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
JPWO2005013938A1 (ja) * 2003-08-06 2006-09-28 エーザイ株式会社 薬物超微粒子の製造法及び製造装置
JP2008535927A (ja) 2005-04-12 2008-09-04 ウィスコンシン アルムニ リサーチ ファンデイション ポリマー及びパッセンジャー薬のミセル組成物
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
KR20100017928A (ko) * 2007-05-25 2010-02-16 더 유니버시티 오브 브리티쉬 콜롬비아 치료제의 경구 투여를 위한 제제 및 관련 방법
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
JP2011500605A (ja) * 2007-10-16 2011-01-06 アルファファーム ピーティーワイ リミテッド 制御放出医薬配合物
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
FR2959133A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Formulation pharmaceutique anticancereuse
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP6095675B2 (ja) * 2011-10-28 2017-03-15 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 骨止血のための非水性組成物、およびそれらを使用し、製造するための方法
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) * 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
DE102012221219B4 (de) 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
US20170050337A1 (en) * 2013-05-02 2017-02-23 Melior Innovations, Inc. Formation apparatus, systems and methods for manufacturing polymer derived ceramic structures
RU2737893C2 (ru) * 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением
CN105233768B (zh) * 2015-09-29 2017-07-21 浙江理工大学 一种制备聚多巴胺‑硅基复合微球的方法及产品
KR102086316B1 (ko) * 2019-09-09 2020-03-09 한국콜마주식회사 경피흡수성이 우수한 화장료 조성물

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745785A (en) 1952-10-29 1956-05-15 American Home Prod Therapeutic composition comprising tabular nu, nu'-dibenzylethylenediamine di-penicillin, and process for preparing same
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4608278A (en) 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5354563A (en) 1985-07-15 1994-10-11 Research Development Corp. Of Japan Water dispersion containing ultrafine particles of organic compounds
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
CA1338736C (fr) 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5174930A (en) 1986-12-31 1992-12-29 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
IL86211A (en) 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
GB8901254D0 (en) 1989-01-20 1989-03-15 Allied Colloids Ltd Particulate materials and their production
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
IL90561A (en) 1988-06-08 1993-08-18 Fountain Pharm Inc Method for making solvent dilution microcarriers
EP0349428B1 (fr) 1988-06-30 1993-01-20 Centre National De La Recherche Scientifique (Cnrs) Procédé de préparation de systèmes colloidaux dispersibles d'une protéine, sous forme de nanoparticules
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
JP2843857B2 (ja) 1988-10-05 1999-01-06 ファルマシア・アンド・アップジョン・カンパニー 反溶剤への沈澱を介する微細分化固体結晶性粉末
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
SE464743B (sv) 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
CH677886A5 (ko) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
FR2651680B1 (fr) 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
DE4005711C1 (ko) 1990-02-23 1991-06-13 A. Nattermann & Cie Gmbh, 5000 Koeln, De
US5078994A (en) 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
IT1246350B (it) 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
CA2078388A1 (en) 1991-10-02 1993-04-03 Mridula Nair Biocompatible emulsion particles
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US5298483A (en) 1992-03-30 1994-03-29 Tropicana Products, Inc. New matter of composition and method for using the same as plant bioregulators
US5389263A (en) 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
DE69309056T2 (de) 1992-06-10 1997-09-18 Nanosystems Llc Oberflaechenmodifizierte nsaid nanopartikeln
SE9202128D0 (sv) 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
US5466646A (en) 1992-08-18 1995-11-14 Worcester Polytechnic Institute Process for the preparation of solid state materials and said materials
US5417956A (en) 1992-08-18 1995-05-23 Worcester Polytechnic Institute Preparation of nanophase solid state materials
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4305003A1 (de) 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FR2703927B1 (fr) 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
SE9303574D0 (sv) 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
UA40634C2 (uk) 1993-11-15 2001-08-15 Зенека Лімітед Мікрокапсула, яка містить суспензію твердої біологічно активної сполуки, і спосіб її одержання
JP2699839B2 (ja) 1993-12-03 1998-01-19 日本電気株式会社 半導体装置の製造方法
IE940292A1 (en) 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
FR2721510B1 (fr) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
RU2147243C1 (ru) 1994-09-27 2000-04-10 Нюкомед Имагинг А/С Контрастное средство
US5720551A (en) 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
ES2154806T3 (es) 1995-02-06 2001-04-16 Elan Pharma Int Ltd Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
WO1996025918A1 (en) 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5605785A (en) 1995-03-28 1997-02-25 Eastman Kodak Company Annealing processes for nanocrystallization of amorphous dispersions
DE69618938T2 (de) 1995-03-28 2002-10-31 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
ES2177592T3 (es) 1995-07-05 2002-12-16 Europ Economic Community Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE69637441T2 (de) 1995-10-17 2009-03-05 Jagotec Ag Verabreichung unlöslicher arzneistoffe
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6231890B1 (en) 1996-05-02 2001-05-15 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
ATE223206T1 (de) 1996-05-07 2002-09-15 Alkermes Inc Verfahren zur herstellung von mikropartikeln
CA2240161C (en) 1996-05-20 2005-05-24 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
CA2263765C (en) 1996-08-19 2010-03-30 Vivorx Pharmaceuticals, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
DE69734988T2 (de) 1996-08-22 2006-09-21 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen stoffen und verfahren zu deren herstellung
US6344271B1 (en) 1998-11-06 2002-02-05 Nanoenergy Corporation Materials and products using nanostructured non-stoichiometric substances
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
US6048550A (en) 1996-10-03 2000-04-11 Chan; Daniel C. F. Hydrophilic microparticles and methods to prepare same
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IT1292142B1 (it) 1997-06-12 1999-01-25 Maria Rosa Gasco Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
BRPI9810945B8 (pt) 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US20020115609A1 (en) 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
WO1999003450A1 (fr) 1997-07-15 1999-01-28 Coletica Particules, en particulier micro- ou nanoparticules de proteines vegetales reticulees, leur procede de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
DE19737481A1 (de) 1997-08-28 1999-03-04 Hoechst Ag Sphärische lineare Polysaccharide enthaltende Mikropartikel
FI973804A (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
US6221322B1 (en) 1997-11-27 2001-04-24 Dowa Mining Co., Ltd Strontium nitrate and method for manufacturing same
EP1039893B1 (en) 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
DE69814918T2 (de) 1997-12-17 2004-03-11 Universidad De Sevilla Vorrichtung und verfahren zur erzeugung von aerosolen für arzneimittelverabreichung
US6066292A (en) 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
JP3696087B2 (ja) 1997-12-31 2005-09-14 チョンワエ ファーマ コーポレーション イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
WO1999049846A2 (en) 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
CA2326485C (en) 1998-04-01 2008-12-09 Rtp Pharma Inc. Anticancer compositions
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DK1071402T3 (da) 1998-04-09 2007-02-19 Hoffmann La Roche Fremgangsmåde til af partikler med (sub)mikronstörrelse ved oplösning i komprimeret gas og overfladeaktive stoffer
FR2777193B1 (fr) 1998-04-14 2001-06-08 Coletica Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie
IL139541A0 (en) 1998-05-20 2004-02-08 Liposome Co Inc Novel particulate formulations
ATE259220T1 (de) 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
JP4693238B2 (ja) 1998-06-19 2011-06-01 オバン・エナジー・リミテッド 水に溶けない化合物のサブミクロン粒子を生成させる方法
FR2780901B1 (fr) 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6238677B1 (en) 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
ATE452651T1 (de) 1998-09-01 2010-01-15 Merrion Res Iii Ltd Orale impfstoff-zusammensetzung
ATE322285T1 (de) 1998-09-01 2006-04-15 Elan Corp Plc Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
AU767737B2 (en) 1998-11-20 2003-11-20 Skyepharma Canada Inc. Method of preparing stable suspensions of insoluble microparticles
JP2002532535A (ja) 1998-12-22 2002-10-02 アメリカ合衆国 水不溶性薬剤送達システム
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
CA2371912C (en) 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0100823D0 (sv) 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
DE10007816A1 (de) 2000-02-21 2001-09-06 Bayer Ag Verfahren zur Herstellung von Nanosuspensionen
AU4724401A (en) 2000-02-28 2001-09-12 Genesegues Inc Nanocapsule encapsulation system and method
JP5102423B2 (ja) 2000-04-20 2012-12-19 オバン・エナジー・リミテッド 改善された水不溶性薬剤粒子の処理
JP4763957B2 (ja) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
CA2419115C (en) 2000-08-15 2011-03-08 Board Of Trustees Of The University Of Illinois Microparticles, and method and apparatus for forming same
ATE424811T1 (de) 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
AU6294501A (en) 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
KR100822684B1 (ko) * 2000-10-04 2008-04-17 교와 핫꼬 고교 가부시끼가이샤 지질막에 의한 미립자의 피복방법
US7105176B2 (en) 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
AU2002222115B2 (en) 2000-11-30 2006-09-28 Vectura Limited Method of making particles for use in a pharmaceutical composition
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
JP4376518B2 (ja) 2000-12-22 2009-12-02 バクスター・インターナショナル・インコーポレイテッド サブミクロン粒子の懸濁物を調製する方法
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
DE60130580T2 (de) 2000-12-27 2008-06-12 Ares Trading S.A. Lipidmikropartikel mittels kryogenischer mikronisierung
JP2004517699A (ja) 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
SE0100822D0 (sv) 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100901D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab New composition
AU2002312777B2 (en) 2001-03-27 2007-07-05 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
KR100607742B1 (ko) 2001-04-03 2006-08-01 쉐링 코포레이션 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물
AR033711A1 (es) 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1628641A2 (en) 2003-05-19 2006-03-01 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers

Also Published As

Publication number Publication date
IL174031A0 (en) 2006-08-01
CN100551365C (zh) 2009-10-21
US20120070498A1 (en) 2012-03-22
ES2388924T3 (es) 2012-10-19
EP1682116A1 (en) 2006-07-26
AU2004289233A1 (en) 2005-05-26
RU2402313C2 (ru) 2010-10-27
NZ546439A (en) 2010-04-30
BRPI0416239A (pt) 2007-01-09
NO20062552L (no) 2006-06-02
CN1870987A (zh) 2006-11-29
US20040245662A1 (en) 2004-12-09
US8067032B2 (en) 2011-11-29
PL1682116T3 (pl) 2012-10-31
IL174031A (en) 2012-04-30
DK1682116T3 (da) 2012-09-03
KR101152458B1 (ko) 2012-06-01
JP2007510657A (ja) 2007-04-26
EP1682116B1 (en) 2012-05-30
CA2540383A1 (en) 2005-05-26
RU2006119916A (ru) 2007-12-20
AU2004289233B2 (en) 2010-10-21
KR20060118455A (ko) 2006-11-23
WO2005046671A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
ZA200603547B (en) Method for preparing submicron particles of paclitaxel
US20040022862A1 (en) Method for preparing small particles
US20040256749A1 (en) Process for production of essentially solvent-free small particles
EP1347747B1 (en) Method for preparing submicron particle suspensions of pharmaceutical agents
US6884436B2 (en) Method for preparing submicron particle suspensions
JP2006524238A5 (ko)
US7511079B2 (en) Methods and apparatuses for the comminution and stabilization of small particles
ZA200304742B (en) Method for preparing submicron particle suspensions.
CA2591554A1 (en) (polyalkoxy)sulfonate surface modifiers
MXPA06005044A (es) Metodo para preparar particulas de submicron de paclitaxe
MXPA06004786A (en) Process for production of essentially solvent-free small particles